Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
TICAR is a small-molecule injectable antibiotic approved in 1976 by GSK. The drug's specific mechanism of action and indications are not currently documented in available data. It represents a legacy product from the pre-modern pharmaceutical era with established clinical utility.
This legacy product is in late-stage lifecycle with minimal active commercial development; associated team size and investment are likely minimal.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Phase 2 Study of MG-K10 in Chronic Spontaneous Urticaria
Investigation of a Remibrutinib- and Omalizumab-based Treatment Algorithm in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Within 24 Weeks
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT001 Following Intravenous Administration in Participants With Chronic Spontaneous Urticaria (CSU)
A Study of MG-K10 in Chronic Spontaneous Urticaria
A Study to Describe the Real-world Effectiveness, Safety and Patterns of Use of Dupilumab in Patients With Chronic Spontaneous Urticaria
Worked on TICAR at GSK? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
TICAR offers limited career growth with zero linked job openings and approaching loss of exclusivity. Roles available are primarily in legacy product management and field sales focused on defensive market maintenance rather than expansion or innovation.